UBS initiated coverage on enGene Holdings with a new price target
$ENGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UBS initiated coverage of enGene Holdings with a rating of Buy and set a new price target of $37.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2025 | $26.00 | Overweight | Piper Sandler |
| 2/14/2025 | $34.00 → $7.00 | Buy → Neutral | UBS |
| 12/23/2024 | $25.00 | Buy | H.C. Wainwright |
| 11/27/2024 | $23.00 | Outperform | Raymond James |
| 11/18/2024 | $18.00 | Mkt Outperform | JMP Securities |
| 8/28/2024 | $30.00 | Outperform | Oppenheimer |
| 4/22/2024 | $30.00 | Overweight | Wells Fargo |
| 4/15/2024 | $34.00 | Buy | Guggenheim |
10-Q - enGene Holdings Inc. (0001980845) (Filer)
8-K - enGene Holdings Inc. (0001980845) (Filer)
8-K - enGene Holdings Inc. (0001980845) (Filer)